权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

CONTROL AND ACTIVATION OF THE TUMOR NECROSIS FACTOR RECEPTORS

肿瘤坏死因子受体的控制和激活

基本信息

批准号：
10092951
负责人：
JAMES Jeiwen CHOU
金额：
$ 79.69万
依托单位：
HARVARD MEDICAL SCHOOL
依托单位国家：
美国
项目类别：
财政年份：
2020
资助国家：
美国
起止时间：
2020-02-01 至 2025-01-31
项目状态：
未结题

来源：
https://reporter.nih.gov/project-details/10092951
关键词：
Address Agonist Antibodies Antibody Affinity Apoptosis Autoimmune Autoimmune Diseases Automobile Driving Back Binding Biochemistry Cells Cessation of life Cryoelectron Microscopy Cytoplasmic Tail Death Domain Environment Excision Family Family member Goals Immune Immunotherapy Ligands Lipid Bilayers Malignant Neoplasms Mediating Membrane Molecular Conformation Mutagenesis Negative Staining OX40 Property Protocols documentation Receptor Activation Research Role Signal Transduction Structure Surface Surveys TNFRSF10B gene TNFRSF1A gene TNFRSF1B gene TNFRSF5 gene TNFRSF8 gene Technology Testing Therapeutic antibodies Tumor Necrosis Factor Activation Tumor Necrosis Factor Receptor Yeasts base cancer immunotherapy dimer family structure high throughput technology inhibitor/antagonist member nanobodies prevent receptor receptor function screening therapeutic development

项目摘要

PROJECT SUMMARY The goal of this proposal is to determine the rules governing the activation of the receptors in the tumor necrosis factor receptors super family (TNFRSF), for aiding the development of therapeutic antibodies targeting these receptors. There are genuine needs for in-depth understanding of the mechanism by which these receptors are activated, as many of them are targets for antibody-based immunotherapy. While receptor activation accompanying receptor clustering is a general phenomenon observed for receptors of the TNFRSF, existing approaches of developing agonistic/antagonistic antibodies rely largely on trial and error, and no correlation between antibody affinity and functionality has been observed. The proposed research is based on our recent finding that, for a few members of the TNFRSF, the receptor transmembrane helix (TMH) alone can mediate higher-order receptor clustering to drive downstream signaling and that an important role of the receptor ectodomain in the absence of ligand is preventing the TMH-mediated receptor activation. Thus developing antibodies that specifically modulate the auto-inhibitory state of the ectodomain would yield more selective and efficient activators or inhibitors of the receptors. To investigate the general applicability of this mechanism, we will perform structural and functional studies of receptor TMH oligomerization and pre-ligand association for other members of the TNFRSF. Based on our understanding of the mechanism of receptor autoinhibition, we will develop high-throughput technology for discovering antibodies that activate or inhibit members of the TNFRSF in conformation-specific manner. Specifically, in Aim 1, we will perform a thorough survey of receptor TMH clustering to identify TNFRSF members with TMHs that are capable of forming higher- order interaction network and driving signaling. In Aim 2, we will characterize the pre-ligand association structures for a few representative members of the TNFRSF to understand how receptor ectodomain physically inhibit TMH clustering. In Aim 3, we will broadly survey the basic requirements of receptor activation to test our proposed 3-2 rule of receptor activation. In Aim 4, we will exploit the autoinhibition concept to implement a yeast display technology to screen for nanobodies/Fabs that specifically break or stabilize the pre-ligand ectodomain association, as means of activating or inhibiting the receptors, respectively. The proposed research will significantly advance our mechanistic understanding of receptor activation for the TNFRSF while potentially discovering specific agonistic or antagonistic agents for several TNFRSF members such as DR5, TNFR1, TNFR2, OX40, 4-1BB, CD40, and GITR, all of which are important immunotherapy targets.

项目总结